Intrinsic molecular subtypes of glioma are prognostic and predict benefit from adjuvant procarbazine, lomustine, and vincristine chemotherapy in combination with other prognostic factors in anaplastic oligodendroglial brain tumors: a report from EORTC study 26951.

L. Erdem-Eraslan; L.A. Gravendeel; J. de Rooi; P.H.C. Eilers; A. Idbaih; W.G.M. Spliet; W.F den Dunnen; J.L. Teepen; P. Wesseling; P.A. Sillevis Smitt; J.M. Kros; T Gorlia; M.J. van den Bent; P.J. French

Intrinsic molecular subtypes of glioma are prognostic and predict benefit from adjuvant procarbazine, lomustine, and vincristine chemotherapy in combination with other prognostic factors in anaplastic oligodendroglial brain tumors: a report from EORTC study 26951.

Translated title of the contribution: Intrinsic molecular subtypes of glioma are prognostic and predict benefit from adjuvant procarbazine, lomustine, and vincristine chemotherapy in combination with other prognostic factors in anaplastic oligodendroglial brain tumors: a report from EORTC study 26951.

L. Erdem-Eraslan
, L.A. Gravendeel
, J. de Rooi
, P.H.C. Eilers
, A. Idbaih
, W.G.M. Spliet
, W.F den Dunnen
, J.L. Teepen
, P. Wesseling
, P.A. Sillevis Smitt
, J.M. Kros
, T Gorlia
, M.J. van den Bent
, P.J. French

Research output: Contribution to journal › Article › Academic › peer-review

Translated title of the contribution	Intrinsic molecular subtypes of glioma are prognostic and predict benefit from adjuvant procarbazine, lomustine, and vincristine chemotherapy in combination with other prognostic factors in anaplastic oligodendroglial brain tumors: a report from EORTC study 26951.
Original language	Undefined/Unknown
Pages (from-to)	328-336
Number of pages	9
Journal	Journal of Clinical Oncology
Volume	31
Issue number	3
Publication status	Published - 2013

Access to Document

http://www.ncbi.nlm.nih.gov/pubmed/23269986

Cite this

Erdem-Eraslan, L., Gravendeel, L. A., de Rooi, J., Eilers, P. H. C., Idbaih, A., Spliet, W. G. M., den Dunnen, W. F., Teepen, J. L., Wesseling, P., Sillevis Smitt, P. A., Kros, J. M., Gorlia, T., van den Bent, M. J., & French, P. J. (2013). Intrinsic molecular subtypes of glioma are prognostic and predict benefit from adjuvant procarbazine, lomustine, and vincristine chemotherapy in combination with other prognostic factors in anaplastic oligodendroglial brain tumors: a report from EORTC study 26951. Journal of Clinical Oncology, 31(3), 328-336. http://www.ncbi.nlm.nih.gov/pubmed/23269986

Erdem-Eraslan, L. ; Gravendeel, L.A. ; de Rooi, J. et al. / Intrinsic molecular subtypes of glioma are prognostic and predict benefit from adjuvant procarbazine, lomustine, and vincristine chemotherapy in combination with other prognostic factors in anaplastic oligodendroglial brain tumors: a report from EORTC study 26951. In: Journal of Clinical Oncology. 2013 ; Vol. 31, No. 3. pp. 328-336.

@article{b181f942eca44d329bade8b01553081d,

title = "Intrinsic molecular subtypes of glioma are prognostic and predict benefit from adjuvant procarbazine, lomustine, and vincristine chemotherapy in combination with other prognostic factors in anaplastic oligodendroglial brain tumors: a report from EORTC study 26951.",

author = "L. Erdem-Eraslan and L.A. Gravendeel and \{de Rooi\}, J. and P.H.C. Eilers and A. Idbaih and W.G.M. Spliet and \{den Dunnen\}, W.F and J.L. Teepen and P. Wesseling and \{Sillevis Smitt\}, P.A. and J.M. Kros and T Gorlia and \{van den Bent\}, M.J. and P.J. French",

year = "2013",

language = "Undefined/Unknown",

volume = "31",

pages = "328--336",

journal = "Journal of Clinical Oncology",

issn = "0732-183X",

publisher = "Lippincott Williams \& Wilkins",

number = "3",

}

Erdem-Eraslan, L, Gravendeel, LA, de Rooi, J, Eilers, PHC, Idbaih, A, Spliet, WGM, den Dunnen, WF, Teepen, JL, Wesseling, P, Sillevis Smitt, PA, Kros, JM, Gorlia, T, van den Bent, MJ & French, PJ 2013, 'Intrinsic molecular subtypes of glioma are prognostic and predict benefit from adjuvant procarbazine, lomustine, and vincristine chemotherapy in combination with other prognostic factors in anaplastic oligodendroglial brain tumors: a report from EORTC study 26951.', Journal of Clinical Oncology, vol. 31, no. 3, pp. 328-336. <http://www.ncbi.nlm.nih.gov/pubmed/23269986>

Intrinsic molecular subtypes of glioma are prognostic and predict benefit from adjuvant procarbazine, lomustine, and vincristine chemotherapy in combination with other prognostic factors in anaplastic oligodendroglial brain tumors: a report from EORTC study 26951. / Erdem-Eraslan, L.; Gravendeel, L.A.; de Rooi, J. et al.
In: Journal of Clinical Oncology, Vol. 31, No. 3, 2013, p. 328-336.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Intrinsic molecular subtypes of glioma are prognostic and predict benefit from adjuvant procarbazine, lomustine, and vincristine chemotherapy in combination with other prognostic factors in anaplastic oligodendroglial brain tumors: a report from EORTC study 26951.

AU - Erdem-Eraslan, L.

AU - Gravendeel, L.A.

AU - de Rooi, J.

AU - Eilers, P.H.C.

AU - Idbaih, A.

AU - Spliet, W.G.M.

AU - den Dunnen, W.F

AU - Teepen, J.L.

AU - Wesseling, P.

AU - Sillevis Smitt, P.A.

AU - Kros, J.M.

AU - Gorlia, T

AU - van den Bent, M.J.

AU - French, P.J.

PY - 2013

Y1 - 2013

M3 - Article

SN - 0732-183X

VL - 31

SP - 328

EP - 336

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

IS - 3

ER -

Erdem-Eraslan L, Gravendeel LA, de Rooi J, Eilers PHC, Idbaih A, Spliet WGM et al. Intrinsic molecular subtypes of glioma are prognostic and predict benefit from adjuvant procarbazine, lomustine, and vincristine chemotherapy in combination with other prognostic factors in anaplastic oligodendroglial brain tumors: a report from EORTC study 26951. Journal of Clinical Oncology. 2013;31(3):328-336.